Pfizer to buy cancer drugmaker Seagen in $43 billion deal

Pfizer Inc. agreed to purchase cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, gaining the company’s antibody drugs that fight tumors. Pfizer will pay $229 a share in cash for Seagen, according a statement Monday, about a third more than the drugmaker’s closing share price Friday.